No Data
No Data
LAVA Therapeutics to Transition to U.S. Domestic Issuer
H.C. Wainwright Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Cuts Target Price to $2
HC Wainwright & Co. Maintains Buy on LAVA Therapeutics, Lowers Price Target to $2
Leerink Partners Downgrades LAVA Therapeutics to Market Perform, Lowers Price Target to $2
Leerink Partners Downgrades LAVA Therapeutics(LVTX.US) to Hold Rating, Announces Target Price $2
Hold Rating on LAVA Therapeutics Amid Uncertainty and Program Discontinuation
Ultratech 152273975 : ya sure it is
Jaguar8 OP 152273975 : Post it in your account not here
Jaguar8 OP 152273975 : You are flooding a lot of this post in all stocks. LOL
ByUncle : Thank you sir
丁 蟹 152273975 : Will it rise?
View more comments...